Shaowei Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shaowei Guo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Guoyan Qi
Center of Treatment of Myasthenia Gravis, People's Hospital of Shijiazhuang, Shijiazhuang, China; Hebei Provincial Key Laboratory of Myasthenia Gravis, Shijiazhuang, China; Hebei Provincial Clinical Research Center for Myasthenia Gravis, Shijiazhuang, China
1 shared publication - Jiandi Huang
The Fourth Department of Oncology, Hebei General Hospital, Shijiazhuang, China
1 shared publication Jin Gao
Department of Thyroid & Breast Surgery Ward, Hebei General Hospital, Shijiazhuang, China
1 shared publicationJing Zhao
The Sixth Department of Oncology, Hebei General Hospital, Shijiazhuang, China
1 shared publicationLin Kang
Department of Pathology, Hebei General Hospital, Shijiazhuang, China
1 shared publication- Qingxia Li
The Fourth Department of Oncology, Hebei General Hospital, Shijiazhuang, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by SAGE Publications in Cancer Control
- Vol. 31
A Review of Advances in Mitochondrial Research in Cancer
Background: Abnormalities in mitochondrial structure or function are closely related to the development of malignant tumors. Mitochondrial metabolic reprogramming provides precursor substances and energy for the vital activities of tumor cells, so that cancer cells can rapidly adapt to the unfavorable environment of hypoxia and nutrient deficiency. Mitochondria can enable tumor cells to gain the ability to proliferate, escape immune responses, and develop drug resistance by altering constitutive junctions, oxidative phosphorylation, oxidative stress, and mitochondrial subcellular relocalization. This greatly reduces the rate of effective clinical control of tumors. Purpose: Explore the major role of mitochondria in cancer, as well as targeted mitochondrial therapies and mitochondria-associated markers. Conclusions: This review provides a comprehensive analysis of the various aspects of mitochondrial aberrations and addresses drugs that target mitochondrial therapy, providing a basis for clinical mitochondria-targeted anti-tumor therapy.
- 1 January 2024
- Published by SAGE Publications in Cancer Control
- Vol. 31
Open AccessA Review of Advances in Mitochondrial Research in Cancer
Background: Abnormalities in mitochondrial structure or function are closely related to the development of malignant tumors. Mitochondrial metabolic reprogramming provides precursor substances and energy for the vital activities of tumor cells, so that cancer cells can rapidly adapt to the unfavorable environment of hypoxia and nutrient deficiency. Mitochondria can enable tumor cells to gain the ability to proliferate, escape immune responses, and develop drug resistance by altering constitutive junctions, oxidative phosphorylation, oxidative stress, and mitochondrial subcellular relocalization. This greatly reduces the rate of effective clinical control of tumors. Purpose: Explore the major role of mitochondria in cancer, as well as targeted mitochondrial therapies and mitochondria-associated markers. Conclusions: This review provides a comprehensive analysis of the various aspects of mitochondrial aberrations and addresses drugs that target mitochondrial therapy, providing a basis for clinical mitochondria-targeted anti-tumor therapy.